## **AMENDMENTS TO THE CLAIMS**

- 1. (Currently Amended) A microparticle comprising:
- (a) a core which comprises a water insoluble polymer or copolymer, and
- (b) a shell which comprises a hydrophilic polymer or copolymer and functional groups which are ionic or ionisable;

said microparticle having a disease associated antigen a human immunodeficiency virus-1 (HIV-1) Tat protein (SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, or 32), or an immunogenic fragment thereof, adsorbed at the external surface.

- 2. (Cancelled).
- 3. (Previously Presented) A microparticle according to claim 1, wherein the water insoluble polymer is poly(styrene).
- 4. (Previously Presented) A microparticle according to claim 1, wherein the water insoluble polymer is poly(methylmethacrylate).
- 5. (Previously Presented) A microparticle according to claim 1, wherein the hydrophilic polymer is hemisuccinated polyvinylalcohol.
- 6. (Previously Presented) A microparticle according to claim 1, wherein the hydrophilic copolymer is a copolymer of methyacrylic acid and ethyl acrylate.

7. (Previously Presented) A microparticle according to claim 1, wherein the particle has a maximum size of from 0.1 to 10μm

8 and 9. (Cancelled).

- 10. (Withdrawn) A method of production of a microparticle according to claim 1, said method comprising:
- (a) polymerizing one or more water insoluble monomers in the presence of one or more hydrophilic polymer by dispersion polymerization to form microparticles; and
  - (b) adsorbing a disease-associated antigen at the external surface of said microparticles.
- 11. (Previously Presented) A pharmaceutical composition comprising a microparticle according to claim 1 and a pharmaceutically acceptable excipient
- 12. (Withdrawn) A method of generating an immune response in an individual, said method comprising administering a microparticle according to claim 1 in a therapeutically effective amount.
- 13. (Withdrawn) A method according to claim 12, wherein the antigen is a human immunodeficiency virus-1 (HIV-1) antigen and the microparticle is administered to the individual to prevent or treat HIV infection or AIDS.

14-16. (Cancelled).